Gadodiamide
- Generic Name
- Gadodiamide
- Brand Names
- Omniscan
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26GdN5O8
- CAS Number
- 131410-48-5
- Unique Ingredient Identifier
- 84F6U3J2R6
- Background
Gadodiamide is a paramagnetic gadolinium-based contrast agent (GBCA) that is used in MR imaging procedures to assist in the visualization of blood vessels. It is intravenously injected and is commonly marketed under the trade name Omniscan.
- Indication
For intravenous use in MRI to visualize lesions with abnormal vascularity (or those thought to cause abnormalities in the blood-brain barrier) in the brain (intracranial lesions), spine, and associated tissues.
- Associated Conditions
- Stenosis, Abnormal vascularity
- Associated Therapies
- -
Safety Evaluation of Linear and Macrocyclic Gadolinium Based Contrast Agents for Patients With Mild to Moderate Renal Insufficiency Undergoing Enhanced Magnetic Resonance Imaging
- Conditions
- Interventions
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2021-03-01
- Lead Sponsor
- The Central Hospital of Lishui City
- Target Recruit Count
- 600
- Registration Number
- NCT04776187
- Locations
- 🇨🇳
Lishui Central Hospital, Lishui, Zhejiang, China
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
- Conditions
- Interventions
- First Posted Date
- 2020-05-04
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Guerbet
- Target Recruit Count
- 2076
- Registration Number
- NCT04373564
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
🇧🇷Hospital Santa Marta, Taguatinga, Distrito Federal, Brazil
Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)
- First Posted Date
- 2009-05-25
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- GE Healthcare
- Target Recruit Count
- 213
- Registration Number
- NCT00908310
- Locations
- 🇺🇸
GE Healthcare, Princeton, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.